Company intelligence / Profile preview

RodaNast

Princeton, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

RodaNast is a specialty pharmaceutical and medical device company focused on developing innovative delivery systems for established therapeutic agents. The company is primarily known for its development of RodaNast (azelastine hydrochloride), a nasal spray formulation designed to treat symptoms of allergic rhinitis and other respiratory conditions. By leveraging advanced nasal delivery technology, RodaNast aims to improve the efficacy and patient experience of allergy treatments. The company's business model centers on the optimization of existing molecules through proprietary delivery platforms to address unmet needs in the respiratory and immunology markets.

Therapeutic areas: ImmunologyDermatology
Modalities: Small moleculeDrug-device combination
Industry: Biotech

Beyond the preview

Go deeper on RodaNast.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RodaNast.

Explore the full profile